Drug Profile
Autologous mesenchymal stem cell therapy - Pharmicell
Alternative Names: Autologous bone marrow-derived mesenchymal stem cell - Pharmicell; Cellgram; Cellgram-ED; Cellgram-LC; Cerecellgram-spine; Hearticellgram-AMI; Immunocellgram; Impocellgram; Livercellgram; Lungcellgram; MSC 1 - FCB Pharmicell; MSC 2 - FCB PharmicellLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator FCB-Pharmicell
- Developer Asan Medical Center; Nonindustrial source; Pharmicell; Samsung Medical Center; Yonsei University Health System
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Myocardial infarction
- Phase III Liver cirrhosis; Stroke
- Phase II/III Spinal cord injuries
- Phase II Adult respiratory distress syndrome; Erectile dysfunction
- Phase I/II Graft-versus-host disease; Parkinson's disease; Renal transplant rejection
- No development reported Brain injuries; Cerebral haemorrhage; Pulmonary fibrosis; Solid tumours
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Liver-Cirrhosis in USA (Intra-arterial, Injection)
- 24 Aug 2021 Pharmicell initiates enrolment in a Long-term follow-up study for Liver cirrhosis in South Korea (Intra-arterial) (NCT05093881)
- 02 Mar 2021 Phase-III clinical trials in Liver cirrhosis in South Korea (Intra-arterial) (NCT04689152)